Complete Resolution of Recurrent Chylothoraces with Acalabrutinib in Chronic Lymphocytic Leukaemia.
DOI:
https://doi.org/10.31344/ijhhs.v7i7000.607Keywords:
Chylothorax, CLL, AcalabrutinibAbstract
Chylothorax is a rare complication of Chronic Lymphocytic Leukaemia (CLL). Previous publications reported variable success rates in management with intensive chemotherapy, which is often unsuitable in CLL patients with chylothoraces due to complications with malnutrition and immunodeficiency. We describe a case of CLL with chylothoraces successfully treated with acalabrutinib, a well-tolerated oral chemotherapy in the class of bruton's tyrosine kinase inhibitor (BTKI). A 76-year-old woman with CLL on active surveillance presented with a persistent dyspnoea and cough. Chest imaging showed bilateral pleural effusions. Therapeutic pleural aspiration yielded 1L of milky fluid with a high triglyceride content suggestive of a chylothorax. Pleural fluid cytology and immunophenotyping confirmed CD5-positive CLL infiltrates. She commenced treatment with steroid and acalabrutinib, but this was initially interrupted by frequent invasive thoracic procedures for reaccumulating chylothoraces. A trial of talc pleurodesis was unsuccessful. An indwelling pleural catheter (IPC) was inserted, allowing uninterrupted treatment. 8 months after commencement of acalabrutinib, repeat chest imaging showed resolution of the effusions, and the IPC was removed. She remained in good remission 14 months later starting treatment. This case highlights the difficulty in managing this complication of CLL, especially due to frequent interruptions of acalabrutinib (associated with increased bleeding risks) due to frequency of invasive pleural procedures required, thereby interrupting treatment efficacy. This necessitated longer-term measures; talc pleurodesis and IPC, which carry a risk in an immunocompromised, malnourished patient. Careful discussion of the risks and benefits allowed us to successfully deliver the treatment and attain good remission with resolution of the effusions.
International Journal of Human and Health Sciences Supplementary Issue 03: 2023 Page: S220
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Muhammad Naim Bin Che Rahimi
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish in the International Journal of Human and Health Sciences agree to the following terms that:
- Authors retain copyright and grant International Journal of Human and Health Sciences the right of first publication of the work.
Articles in International Journal of Human and Health Sciences are licensed under a Creative Commons Attribution 4.0 International License CC BY-4.0.This license permits use, distribution and reproduction in any medium, provided the original work is properly cited.- Authors are able to enter into separate, additional contractual arrangements for the distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted to post their work online (e.g., in institutional repositories or on their website) as it can lead to productive exchanges, as well as greater citation of published work.
